# ZYNYZ

NDC: 50881-006
Generic name: retifanlimab-dlwr
Labeler / Manufacturer: Incyte Corporation
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION
Routes: INTRAVENOUS
Marketing started: 20230322

FDA application: BLA761334

## Active ingredients

- RETIFANLIMAB: 25 mg/mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"50881-006"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=50881-006
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=109648d0-d30a-42fc-8273-39cb1540a751
